Glioblastoma Multiforme is a fast-growing type of central nervous system tumor that forms from glial (supportive) tissue of the brain and spinal cord and has cells that look very different from normal cells. Glioblastoma multiforme usually occurs in adults and affects the brain more often than the spinal cord. Also called GBM, glioblastoma, and grade IV astrocytoma.
Glioblastoma is the most common malignant brain tumor in adults. Roughly five in every 100,000 people develop this type of cancer each year.
A compound found in brown seaweeds could help to treat one of the most common and aggressive forms of malignant brain tumour.
Scientists have identified key molecules that mediate radioresistance in glioblastoma multiforme; these molecules are a potential target for the treatment of this brain cancer.
Investigators at Rutgers Cancer Institute of New Jersey have developed a novel approach for utilizing 4-dimensional (4D) printing of arrays that transform from cell-culture inserts into histological cassettes that hold patient tissue samples for rapid programmable drug testing.
Osteosarcoma, a common bone cancer in dogs, affects more than 10,000 dogs in the U.S. each year. While chemotherapy is generally effective at killing some of the cancer cells, the numerous side effects can be painful and often a subset of cancer cells exist that are resistant to chemotherapy.
Glioblastomas are the most common malignant brain tumors in adults. Treatment options are extremely limited and usually not effective, leading to death for most patients within 12-18 months of diagnosis.
An interview discussing the use of spherical nucleic acids (SNAs) and what they show about the importance of structure in pharmaceutical development.
A new machine learning approach classifies a common type of brain tumor into low or high grades with almost 98% accuracy, researchers report in the journal IEEE Access.
Glioblastoma multiforme is an aggressive form of cancer in the brain that is typically fatal. But new findings by VCU Massey Cancer Center and VCU Institute of Molecular Medicine researchers could help increase the effectiveness of the most common current treatments with the addition of lumefantrine, an FDA-approved drug used to treat malaria.
Scientists are developing a combined vaccine to fight the most deadly form of brain cancer.
When you're facing a cancer diagnosis with an average survival span of 12 to 18 months, every milestone is a victory.
Researchers at EMBL's European Bioinformatics Institute and the Francis Crick Institute have analyzed the whole genomes of over 2600 tumors from 38 different cancer types to determine the chronology of genomic changes during cancer development.
Lab-grown brain organoids developed from a patient's own glioblastoma, the most aggressive and common form of brain cancer, may hold the answers on how to best treat it.
A new engineering solution may help deliver tumor killing drugs directly to the brain tumor without the toxic body effects of systemic chemotherapy. The new study published in the journal Nature Scientific Reports reports on the use of coaxial electrospinning, an industrial fabrication technology, in the production of membranes that incorporate drugs to treat glioblastoma multiforme (GBM), an aggressive cancer of the brain.
Researchers from the University of São Paulo in Brazil have developed a strategy for treating the most aggressive type of brain cancer in adults that combines a photoactive molecule and a chemotherapeutic agent - both encapsulated in protein-lipid nanoparticles.
Chemists from Far Eastern Federal University's School of Natural Sciences developed a new method to synthesize biologically active derivatives of fascaplysin -- cytotoxic pigment of a sea sponge. For the first time, they got a sufficient amount of 3-bromofascaplysin and 3,10-dibromofascaplysin, which were known before but were not available for study.
Mount Sinai researchers have identified a targeted therapy for adolescent patients with neuroblastoma, a deadly pediatric nerve cancer, who would otherwise have no treatment options, according to a study published in October in Cancer Cell.
Children with recurrent brain tumors or newly diagnosed, particularly aggressive tumors called diffuse intrinsic pontine gliomas are being enrolled in the first study to examine the efficacy of a drug that inhibits an enzyme these tumors use to protect themselves from the child's natural immune response.
The research team of Miguel Hernández Univeristy (UMH) professor Salvador Martínez and the team of researcher Rut Valdor, from the University of Murcia, have showed how the glioblastoma - the most common brain cancer - "hijacks" the defensive cells that surround the blood vessels of the brain to deactivate their anti-tumour action, and forces them to work to spread the tumour.
Investigators at the University of Cincinnati are studying whether or not a modified Atkins-type ketogenic diet could help make treatments for a common, but dangerous, type of brain cancer called glioblastoma more effective.